All News

exhibitor.floor.ACR

EULAR 2023 – Day 3 Report

d Jack Cush, MD

Day 3 was a sunny warm day in Milan at the 2023 EULAR Congress meeting. Here are a few of my favorite abstracts from today.

Read Article
38420215_s.jpg

RA and cancer risk in the biologic era

d Aurelie Najm, MD, PhD

A nationwide population-based study, by Beydon et al. (OP0044), has performed a more recent (2010-2020) analysis of cancer incidence in people living with RA within the French national claim database, compared to general population, measured in the French Network of Population-Based Cancer Registries.

Read Article
artificial intelligence machine learning computer

AI in RA: the story grows along the patient pathway

d Antoni Chan, MD, PhD

The use of artificial intelligence to analyse large data sets using its subset component machine learning has taken centre stage recently in the management of rheumatic conditions, including rheumatoid arthritis. The use of AI is now starting to cross the various stages in patient care from detection, diagnosis, treatment and the prediction of long-term outcome.

Read Article
pregnant, pregnancy, mother, fertility

Unmasking Lupus Pregnancy: Adherence and Drug Monitoring Dilemmas

d Bella Mehta, MBBS, MS

Risk of poor pregnancy outcomes in lupus patients continues to remain high, especially in the setting of high disease activity. Preliminary data from a lupus pregnancy LEGACY cohort presented at EULAR 2023 raise concern.

Read Article
A mono therapy study RCT of TLL-018 vs #Tofa in RA subanalyses of previous JAKi exposure have not been done. Pts could have failed #Tofacitinib & enrolled so data could be divided to determine how this group responded. Safety looked good in both Rx LB0001 @RheumNow #EULAR2023 https://t.co/4kBHxWmk0q

Links:

Janet Pope Janetbirdope ( View Tweet)

#EULAR2023 #LB0001 Data from Phase 2 RCT in China showed novel therapy, TLL-018, dual JAK1/Tyk2-i showed superior response to Tofacitinib. Safety profile were similar. Interesting to see data in Phase 3. May be an option for difficult to treat Rheumatoid Arthritis @RheumNow https://t.co/Db5QhzNUC1
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2023 Before the Highlights sessions, do come along to a session on Novel Mechanism of Cell Death at 12 noon Space 3. We have great line up of speakers 👍🏽🙌🏻 https://t.co/ObcC11uxz0
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
What about a new oral drug in active #rheumatoid #arthritis vs #JAKi #Tofacitinib? TLL-018 a potent JAK1/TYK2 inhibitor was compared with #Tofa and dose ranging of 10, 20, 30 mg of TLL-018 and many Pts w past TNFi and w JAKi. High dose won #EULAR2023 @RheumNow @eular_org LB0001 https://t.co/UXhT7LV1oD
Janet Pope Janetbirdope ( View Tweet)
DISSOLVE 1&2 SEL 212 = tolerogenic nanoparticles containing rapamycin (SEL-110) + pegadricase (SEL-037) Meets primary endpoint in 2 RCTs High dose response 56% & 46% 97% reduction in sUA Infusion reaction 4%, stomatitis 8% Anaphylaxis 4 cases @RheumNow #EULAR23 LB0002 https://t.co/21HieM7NfC
Aurelie Najm AurelieRheumo ( View Tweet)
#EULAR23 – Day 1 Report The opening Plenary session and presidential address was followed by a number of overview and review sessions with but a half-day of abstracts presentations, on several therapeutic areas including JIA, COVID and more. https://t.co/7TayWx8SR6 https://t.co/p1K1MduPmO

Links:

Dr. John Cush RheumNow ( View Tweet)
Promising new therapies in SLE Dr. Yuz Yusof ( @Yuz6Yusof ) weighs in. The pharmacology treatment in SLE is a rapidly expanding field of research that provides excitement and optimism to both the patients and the clinicians. https://t.co/0G6EMYp2mb https://t.co/Yc31sR4fRE

Links:

Dr. John Cush RheumNow ( View Tweet)
An update on JAK inhibitors and cardiovascular risks Dr. Antoni Chan ( @synovialjoints ) shares #EULAR23 developments on JAK/TYK2 inhibitors. https://t.co/yZqHEg73bn https://t.co/CzVH62LEgL

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Eular 2023 Daily Recap Series https://t.co/oZXuyv8wL5

Links:

Dr. John Cush RheumNow ( View Tweet)

The key data for treating clinically suspect arthralgias (CSA): TREAT-EARLIER (MTX) ARIAA, APIPPRA (abatacept) but what we need to do going forward: stratify pts better for studies predict individual risk better, to weight up risk-benefit of intervention #EULAR2023 @RheumNow https://t.co/h3gNIyLxPY
David Liew drdavidliew ( View Tweet)
Key arguments for CSA skeptics: - definitions, imaging aren’t anywhere near as good as our own suspicion as clinicians is - we still struggle to prevent RA - it’s easy to go down a therapeutic slippery slope, and hard to track back - labels are hard to remove #EULAR2023 @RheumNow https://t.co/4adop3IR8g
David Liew drdavidliew ( View Tweet)
Presenting work to improve referrals from primary care, reducing delays in diagnosis in rheumatic conditions. Sharing the set up of Rheumatology Academy and Collaborative Network (RheumACaN) and the impact it is making @RBNHSFT @NASSexercise @RheumatologyUK @RheumNow #EULAR2023 https://t.co/v0BBRiFtEy
Dr. Antoni Chan synovialjoints ( View Tweet)
Check out RheumNow's #EULAR23 coverage! https://t.co/rGBWF0lx4g https://t.co/6SEon6poi4

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2023 annual meeting is sponsored in part by Bristol Myers Squibb. All content is chosen by RheumNow and its faculty.

Dr. John Cush RheumNow ( View Tweet)

RheumNow Eular 2023 Daily Recap Series https://t.co/ScW9jWvzl9

Links:

Dr. John Cush RheumNow ( View Tweet)

So Annette van der Helm-van Mil makes some clear arguments about why CSA is real. But Filip Van den Bosch gives his disclosure: the clinical rheumatologist’s inherent skepticism of ‘early disease’ #EULAR2023 @RheumNow https://t.co/GbaBhQE5AB
David Liew drdavidliew ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×